Innate Pharma (IPHA) EBITDA (2007 - 2026)
Innate Pharma (IPHA) EBITDA from Jun 30, 2007 to Mar 31, 2026. The TTM Innate Pharma (IPHA) EBITDA is -$124M. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Annual EBITDA
Quarterly EBITDA
Innate Pharma (IPHA) EBITDA CAGR table
| Period | CAGR |
|---|---|
| 1 Year TTM | +99.98% |
| 3 Years TTM | +95.70% |
| 5 Years TTM | +8.40% |
| 10 Years TTM | +27.26% |
| All Time TTM | +10.93% |
Annual EBITDA change of Innate Pharma (IPHA)
| Year | EBITDA | Change |
|---|---|---|
| 2026 | -$35M | -30.80% |
| 2025 | -$51M | +5.57% |
| 2024 | -$49M | +2289.76% |
| 2023 | -$2.03M | -84.48% |
| 2022 | -$13M | -73.34% |
| 2021 | -$49M | -402.25% |
| 2020 | $16M | -169.50% |
| 2019 | -$23M | +518.17% |
| 2018 | -$3.78M | -91.17% |
| 2017 | -$43M | -478.00% |
| 2016 | $11M | -228.98% |
| 2015 | -$8.78M | -57.63% |
| 2014 | -$21M | +689.95% |
| 2013 | -$2.62M | +13.04% |
| 2012 | -$2.32M | -69.05% |
| 2011 | -$7.50M | -54.52% |
| 2010 | -$16M | -20.44% |
| 2009 | -$21M | +18.88% |
| 2008 | -$17M | +40.65% |
| 2007 | -$12M | N/A |
Comparison Innate Pharma (IPHA) five years EBITDA CAGR with competitors
Innate Pharma (IPHA) five years EBITDA CAGR is 39.74%.